Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial (Q57579927)

From Wikidata

Jump to navigation Jump to search

scientific article published on 09 August 2012

Language	Label	Description	Also known as
English	Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial	scientific article published on 09 August 2012

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

0 references

phase III clinical trial

1 reference

based on heuristic

inferred from title

multicenter clinical trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Tadeusz Pieńkowski

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Vladimir Semiglazov

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

5

object named as

Bert Lum

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

author name string

Gustavo Ismael

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Roberto Hegg

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Susanne Muehlbauer

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Dominik Heinzmann

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Sung-Bae Kim

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Mikhail Lichinitser

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Bohuslav Melichar

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Christian Jackisch

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

publication date

9 August 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Lancet Oncology Commission

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

869-878

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Locally recurrent or metastatic breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

A recombinant human enzyme for enhanced interstitial transport of therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy of adjuvant chemotherapy according to hormone receptor status in young patients with breast cancer: a pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970329-7

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(12)70329-7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22884505%20AND%20SRC:MED&resulttype=core&format=json

10 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57579927&oldid=1756754986"